Entheon Biomedical - CEO, Timothy Ko.
CEO, Timothy Ko.
Source: Entheon Biomedical.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Entheon Biomedical (ENBI) subsidiary, HaluGen Life Sciences, has partnered with 3W Wellness to drive brand awareness
  • 3W Wellness is an organization committed to sharing trusted, research-based content and resources for safe, structured and responsible psychedelics use
  • The companies will focus on expanding access to and visibility for HaluGen’s psychedelics genetic test kit
  • The genetic test identifies specific DNA biomarkers to gauge risks and potential adverse reactions from hallucinogenic drugs
  • Entheon is a biotechnology company developing safe and effective psychedelic therapeutic products
  • Entheon Biomedical (ENBI) closed down 2.63 per cent trading at $0.37 per share

Entheon Biomedical (ENBI) subsidiary, HaluGen Life Sciences, has partnered with 3W Wellness to drive brand awareness.

3W Wellness is an organization committed to sharing trusted, research-based content and resources for safe, structured and responsible psychedelics use.

The companies will focus on expanding access to and visibility for HaluGen’s psychedelics genetic test kit, which was launched in the U.S. on June 6, 2021.

The genetic test identifies specific DNA biomarkers to gauge risks and potential adverse reactions from hallucinogenic drugs. The test provides personalized reports and actionable insights directly to a user’s smartphone.

Timothy Ko, Entheon Biomedical’s CEO, commented, 

“We’re excited to team up with a leader in the psychedelic space such as Third Wave and look forward to our collaboration and to the increased exposure that this relationship will provide. This is just one of many steps we plan to take as we work to develop channels for the commercial development of HaluGen’s psychedelics genetic test. Our mutual vision to help create safer psychedelic experiences and help people make informed choices remains paramount to the core mission of Entheon.”

Paul Austin, founder and CEO of 3W Wellness, added,

“Since our establishment in 2015, we’ve focused on providing our community with access to education and resources so people can feel safe, supported, and empowered as they follow their path towards personal transformation. We believe HaluGen’s psychedelics genetic test hits all those criteria by helping people understand their sensitivities and risks in advance, paving the way for people to integrate intentional, measured, and responsible psychedelic use into their everyday lives.”

Entheon is a biotechnology company developing safe and effective psychedelic therapeutic products.

Entheon Biomedical (ENBI) closed down 2.63 per cent trading at $0.37 per share.

More From The Market Herald

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.
Nanalysis (TSXV:NSCI) - Founder & CEO, Sean Krakiwsky.

" Nanalysis (TSXV:NSCI) signs $160M security contract

Nanalysis Scientific (NSCI) has signed a six-year $160 million contract with Canadian Air Transportation Security Authority (CATSA).
Lifeist Wellness Inc - CEO, Meni Morim

" Lifeist Wellness (TSXV:LFST) announces sale of Swedish subsidiary Findify

Lifeist Wellness (LFST) announced the sale of Findify AB, the company’s Swedish subsidiary that operates an AI-powered product search and discovery platform.

" DIAGNOS (TSXV:ADK) testing autonomous AI solutions for diabetic retinopathy screening

Diagnos (ADK) is launching the testing phase for autonomous artificial intelligence solutions dedicated to diabetic retinopathy screening.